DGAP-News
PharmaSGP: Revenue growth in 2020 despite declining markets - Seite 4
CONTACT
cometis AG
Claudius Krause
Phone: +49-611-20585528
Email: ir@sgp-pharma.com
ABOUT PHARMASGP HOLDING SE
PharmaSGP is a leading consumer health company focusing on non-prescription pharmaceuticals sold over the counter ("OTC"). PharmaSGP's products are sold exclusively through pharmacies. Its products are based on natural active pharmaceutical ingredients with documented efficacy and fewer known side-effects than most chemical-based pharmaceuticals.
The Company's core brands cover chronic indications, including rheumatic pain, nerve pain and other age-related ailments. In Germany, PharmaSGP is the market leader for systemic, chemical-free pain remedies with its brand families RubaXX(R) for rheumatic pain and Restaxil(R) for neuralgic pain (nerve pain). PharmaSGP also offers leading products against sexual weakness and vertigo. Since the launch of the first product from the current portfolio in Germany in 2012, we have successfully exported our business model to other European countries such as Austria, Italy, Belgium, Spain and France.
PharmaSGP generated revenues of €62.6 million at an EBIT margin of 26.1% in 2020.
In order to further expand its competitive position, PharmaSGP plans to increase the number of indications covered by PharmaSGP's product offering, leverage established brand families to introduce new chemical-free OTC and other healthcare products, increase PharmaSGP's European footprint, and accelerate its growth strategy by capitalizing on selected M&A opportunities.
Lesen Sie auch
31.03.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
Language: | English |
Company: | PharmaSGP Holding SE |
Lochhamer Schlag 21 | |
82166 Gräfelfing | |
Germany | |
E-mail: | ir@sgp-pharma.com |
Internet: | https://pharmasgp.com |
ISIN: | DE000A2P4LJ5 |
WKN: | A2P4LJ |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich |
EQS News ID: | 1179866 |